The Korean Journal of Hepatology · 2011 · 81 citations · 27 references
MedicineEndocrinologyClinical NutritionMetabolic PhysiologyMetabolismInsulin ResistanceLiver DiseaseLiver Function TestsMetabolic DiseaseMetabolic Liver DiseaseMetabolic SyndromeGamma-glutamyl TransferaseHepatic Function TestsHepatic Insulin ResistanceInterpretation Of Liver Function TestsLiver Enzyme AbnormalitiesNonalcoholic Fatty Liver Disease-associated Insulin ResistanceReference Ranges For Liver Function TestsSerum Alanine Aminotransferase
BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) has recently been found to be a novel component of metabolic syndrome (MS), which is one of the leading causes of chronic liver disease. The serum alanine aminotransferase (ALT) and ⟨-glutamyltransferase (GGT) levels are suggested to affect liver fat accumulation and insulin resistance. We assessed the associations of serum ALT and GGT concentrations within the reference ranges with MS and NAFLD. METHODS: In total, 1,069 subjects enrolled at the health promotion center of Wonkwang University Hospital were divided into 4 groups according to serum ALT and GGT concentrations levels within the reference ranges. We performed biochemical tests, including liver function tests and lipid profiles, and diagnosed fatty liver by ultrasonography. Associations of ALT and GGT concentrationgrading within the reference range with fatty liver and/or MS were investigated. RESULTS: The presence of MS, its components, and the number of metabolic abnormalities [except for high-density lipoprotein-cholesterol (HDL-C) and fasting blood glucose] increased with the ALT level, while the presence of MS, its components, and the number of metabolic abnormalities (except for HDL-C) increased with the GGT level. The odds ratios for fatty liver and MS increased with the ALT level (P⟨0.001 and P=0.049, respectively) and the GGT level (P=0.044 and P=0.039, respectively). CONCLUSIONS: Serum ALT and GGT concentrations within the reference ranges correlated with the incidence of NAFLD and MS in a dose-dependent manner. There associations need to be confirmed in large, prospective studies.
27
The metabolic syndrome—a new worldwide definition
K. G. M. M. Alberti, Paul Zimmet, Jonathan E. Shaw · The Lancet · 2005 · 9.3K citations
Nonalcoholic Fatty Liver Disease
Giulio Marchesini, Mara Brizi, Giampaolo Bianchi et al. · Diabetes · 2001 · 2.6K citations · Full text
Medicine, Pathology, Hepatology +11
The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease
Masahide Hamaguchi, Takao Kojima, Noriyuki Takeda et al. · Annals of Internal Medicine · 2005 · 1.1K citations
Ultrasound scanning in the detection of hepatic fibrosis and steatosis.
S.H. Saverymuttu, A.E.A. Joseph, J. D. Maxwell · BMJ · 1986 · 850 citations · Full text